Trusted Resources: Evidence & Education
Scientific literature and patient education texts
The Teen Symposium: Engaging Adolescents and Young Adults With Sickle Cell Disease in Clinical Care and Research
source: Clinical Practice in Pediatric Psychology
year: 2020
authors: Crosby, Lori E. Strong, Heather Johnson, Alisha Mitchell, Monica J
summary/abstract:Objective:
In the United States, sickle cell disease (SCD) is the most prevalent genetic disorder affecting African American and Hispanic youth. Disparities in care have been reported for this population with adolescents and young adults (AYA) with SCD at increased risk for poor health outcomes. It is essential that AYA with SCD receive high-quality care and have access to disease-modifying therapies, yet engaging them in their care and clinical research studies to discover new treatments remains a challenge.
Method:
Our team developed an innovative approach to engage AYA with SCD in clinical care and research: the SCD Teen Symposium, which uses motivational interviewing strategies to educate AYA with SCD, their family members, and friends while providing concurrent opportunities for research participation.
Results:
Over a 6-year period, 81 AYA with SCD (47% male; Mage = 14.58, SD = 2.9) and 162 family and friends (48% male; Mage = 13.37, SD = 2.1) participated. Participants rated the symposium as acceptable (Mrating = 1.74, SD = 0.85) on a scale from 1 (excellent) to 5 (poor), and 72% reported they would recommend it to others. Research was rated as very important (Mrating = 1.21, SD = 0.46) by 81% of attendees on a scale from 1 (very important) to 4 (not important), and 82% reported increased trust in research. AYA suggested improvements including separate programming for younger and older teens.
Conclusions:
Results support the feasibility of the Teen Symposium as a model for increasing trust and potentially increasing participation in research. Future studies will determine whether it can be disseminated by other SCD clinics.
DOI: 10.1037/cpp0000323
read more
Related Content
-
Researchers raise funds for phase 1 trial to test medical cannabis in sickle cell diseaseThe Sickle Cell Foundation of Georgia ...
-
Randomized Feasibility Trial to Improve Hydroxyurea Adherence in Youth Ages 10–18 Years Through Community Health W...Introduction: The main therapeutic int...
-
Imara’s IMR-687 for SCD Receives FDA Rare Pediatric Disease DesignationThe U.S. Food and Drug Administration (F...
-
FDA Awards $2M to Phase 2 Trial of Vitamin D for Reducing Risk of SCD Respiratory ComplicationsThe U.S. Food and Drug Administration (F...
-
Prevention of morbidity in sickle cell disease phase II (Improvement of Pain and Quality of Life in Children with Si...In addition to pain, sickle cell anaemia...
-
A Teenager’s Breakthrough Gene Therapy for Sickle Cell DiseaseMeet Helen Obando, a shy 16-year-old who...
-
California’s Stem Cell Agency Invests in Stem Cell-Based Therapies Targeting Sickle Cell Disease and CancerThe California Institute for Regenerativ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.